Cardiovascular

Amarin Receives Approval for VAZKEPA to Reduce Cardiovascular Risk

March 30, 2021 · 1 min read

A round of applause for our research site physicians Dr Sam Henein and Dr Michael O’Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study! After more than a decade of development and testing, VAZKEPA becomes the first and only European Commission-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides and other risk characteristics as studied in REDUCE-IT. Keep up the amazing work guys

https://investor.amarincorp.com/news-releases/news-release-details/amarin-receives-european-commission-ec-approval-vazkepa-reduce

This article is general health information, not medical advice. Talk to your own doctor about your situation.
The Canadian Health Newsletter

Get Cardiovascular research updates by email

One email a month: new studies and plain-language articles from our health library.

Study alerts: an email only when a matching study opens. Community: our research team may contact you about studies that may fit. Join the community

Conditions in this article

Read the plain-language guide

CardiovascularCardiovascular disease is a group of conditions affecting the heart and the blood vessels that carry blood around...Read the guide HypertriglyceridemiaCholesterol is a fatty substance your body needs, carried around in the blood by particles. Hyperlipidemia, usually called...Read the guide
From reading to research

Studies on this topic, enrolling now

See all Cardiovascular trials
Recruiting
Overweight and Obesity
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight Without Type 2 Diabetes
See if you may qualify — A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight Without Type 2 Diabetes →Study details — A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight Without Type 2 Diabetes →
Recruiting
Cardiovascular
Study of Orforglipron in Participants With Peripheral Artery Disease
See if you may qualify — Study of Orforglipron in Participants With Peripheral Artery Disease →Study details — Study of Orforglipron in Participants With Peripheral Artery Disease →
Recruiting
Chronic Kidney Disease
A Study for Adults With Atherosclerotic Cardiovascular Disease and/​or Chronic Kidney Disease
See if you may qualify — A Study for Adults With Atherosclerotic Cardiovascular Disease and/​or Chronic Kidney Disease →Study details — A Study for Adults With Atherosclerotic Cardiovascular Disease and/​or Chronic Kidney Disease →

Keep reading

All articles
CardiovascularArrowhead Pharmaceuticals’ New Drug Plozasiran Shows Promise in Treating Rare Genetic Disease2 min readCardiovascularThe Future of Longevity: What’s Coming Next5 min readCardiovascularGene Editing Could One Day Replace Cholesterol Drugs, Early Study Suggests1 min read

Ready when you are

See which studies you may qualify for

About five minutes. Free, and no obligation to take part.

Find your study match Not ready yet? Join the community and hear when a study may match the health areas you care about.